WHO has kindly made available its conflict of interest guidelines. Apparently they are not available from the public web page. Attached are two documents:
A few of the many interesting provisions follow:
I. MEANING OF "CONFLICT OF INTEREST"
European members of WHO Executive Board take hard line on nomination of Novartis official to R&D groupSubmitted by thiru on 19. January 2011 - 7:38
At the 128th meeting of the WHO Executive Board (EB), the European members of the board are reportedly taking a hard line on the proposal by Switzerland to have Paul Herrling, an executive of Novartis, appointed to the WHO Consultative Expert Working Group (CEWG) on R&D financing. Our earlier blogs on this controversy are available here and here).
Conflicts of Interest, and the WHO evaluation of the FRIND and the PDP Plus funding proposals by the CEWGSubmitted by thiru on 18. January 2011 - 11:19
This note provide additional context for those who are just now following the issue of conflicts of interest and the WHO Consultative Expert Working Group (CEWG) on R&D Financing.
The CEWG follows a controversial, flawed and failed effort by an earlier group, the WHO Expert Working Group (EWG) on R&D Financing, to:
At the end of the day on Monday, the 128 WHO Executive Board meeting took the agenda item for creation of a new R&D Financing consultative expert working group (CEWG). (Yesterday's blog on this topic is here)
World Health Organization Executive Board to create new consultative expert working group on R&D FinancingSubmitted by James Love on 17. January 2011 - 8:55
Today the WHO is expected to take up the Report by the Secretariat on "the Establishment of a consultative expert working group on research and development: financing and coordination." (link here).
European Commission (DG 1) note on the WHO's Revised Drug Stategy
DIRECTORATE GENERAL 1
EXTERNAL RELATIONS: COMMERCIAL POLICY AND RELATIONS WITH NORTH AMERICA. THE
FAR EAST, AUSTRALIA AND NEW ZEALAND
Directorate D -Sectoral trade questions, market access
New technologies, Intellectual property, public procurement
Brussels, 5 October 1998
1/D/3/BW D (98)
The following are selected documents from the 1998 to 1999 WHO debate of the revised drug strategy.
- The January 1998 proposal for the Revised Drug Strategy (EB101.R24)
- May 27, 1998 Department of State cable: Revised Drug Strategy At W.H.O.: Atmospherics Of The Debate, And Recommended Plan Of Action.
- European Commission October 5, 1998 memorandum on the WHO Revised Drug Strategy negotiation
A pdf copy of the resolution is attached to this page.
THE FIFTY-SECOND WORLD HEALTH ASSEMBLY
Agenda Item 13
May 24, 1999
Revised Drug Strategy
The Fifty-second World Health Assembly,
Recalling resolution WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14;
Having considered the report of the Director-General on the revised drug strategy;